

## Guest Editorial

# Highlight: Self-renewal signaling in stem cells

A number of ground-breaking studies recently identified sets of nuclear factors that together have the unique ability to 'reset' an adult differentiated cell type and to 'erase' all previous fate decisions and the transcriptional programs that determine phenotype and function of a differentiated cell (Takahashi et al., 2007; Wernig et al., 2007; Yu et al., 2007). As a result, 'reprogrammed' cells assume a phenotype closely resembling embryonic stem cells and functional studies so far suggest that these cells, termed 'induced pluripotent stem cells (iPS)', also share fundamental functional characteristics with embryonic stem cells, including self-renewal capacity and pluripotency. The iPS concept, reprogramming of somatic cells into stem cells and its obvious potential for regenerative medicine (Hanna et al., 2007), electrified the scientific community since its confirmation in 2007. However, the question of which signaling pathways are required for stem cells to maintain an undifferentiated state and their self-renewal capacity has received relatively little attention.

This issue of *Biological Chemistry* presents a series of articles that all focus on transcriptional regulation and signal transduction pathways that are active in stem cell populations to ensure maintenance of inherent stem cell self-renewal capacity. Reflecting different types of stem cells, self-renewal signaling can occur at multiple levels: articles by Cantz, Edenhofer, Kögler and colleagues highlight roles of the transcription factor OCT4 in pluripotent stem cell populations, while Melchior et al. study the role of the WNT receptor FZD7 in self-renewal signaling of pluripotent embryonic stem cells. However, self-renewal also occurs in bone marrow-derived stem cell populations, including multipotent mesenchymal (Angelov and colleagues) and hematopoietic stem cells (articles by the groups of Dittmar, Giebel and Gratwohl). While central concepts of current stem cell biology are based on classical experiments in the hematopoietic system (Humphries et al., 1981; Spangrude et al., 1988; Osawa et al., 1996), the notion of stem cells in tumors and their requirement for the development of a heterogeneous malignant cell population, as discussed by Dirk Kabelitz, emerged only recently. While the 'cancer stem cell' concept is still controversial to some extent (Kelly et al., 2007), a link between stem cells and cancer is strongly supported by the fact that potent oncogenes, including MYC, OCT4 and RAS (as discussed by Rolf Heumann), have an important role in stem cell self-renewal signaling.

I would like to thank the Editors of *Biological Chemistry*, the Editorial staff, in particular the Editor-in-Chief,

Helmut Sies, and the Managing Editor, Torsten Krüger, as well as the contributing authors and all the experts in the field, who served as reviewers for the articles published in this highlight issue. I would like to thank Ira Herrmann, the Managing Director of the Stem Cell Network North Rhine-Westphalia, and its Chairman, Hans Schöler, for their continuous support and encouragement for this initiative.

## References

- Hanna, J., Wernig, M., Markoulaki, S., Sun, C.W., Meissner, A., Cassady, J.P., Beard, C., Brambrink, T., Wu, L.C., Townes, T.M., and Jaenisch, R. (2007). Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. *Science* 318, 1920–1923.
- Humphries, R.K., Eaves, A.C., and Eaves, C.J. (1981). Self-renewal of hemopoietic stem cells during mixed colony formation *in vitro*. *Proc. Natl. Acad. Sci. USA* 78, 3629–3633.
- Kelly, P.N., Dakic, A., Adams, J.M., Nutt, S.L., and Strasser, A. (2007). Tumor growth need not be driven by rare cancer stem cells. *Science* 317, 337.
- Osawa, M., Hanada, K., Hamada, H., and Nakauchi, H. (1996). Long-term lymphohematopoietic reconstitution by a single CD34-low/negative hematopoietic stem cell. *Science* 273, 242–245.
- Spangrude, G.J., Heimfeld, S., and Weissman, I.L. (1988). Purification and characterization of mouse hematopoietic stem cells. *Science* 241, 58–62.
- Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., and Yamanaka, S. (2007). Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell* 131, 861–872.
- Wernig, M., Meissner, A., Foreman, R., Brambrink, T., Ku, M., Hochedlinger, K., Bernstein, B.E., and Jaenisch, R. (2007). *In vitro* reprogramming of fibroblasts into a pluripotent ES-cell-like state. *Nature* 448, 318–324.
- Yu, J., Vodyanik, M.A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J.L., Tian, S., Nie, J., Jonsdottir, G.A., Ruotti, V., Stewart, R., et al. (2007). Induced pluripotent stem cell lines derived from human somatic cells. *Science* 318, 1917–1920.

Markus Müschen  
Leukemia Research Program  
Children's Hospital Los Angeles  
University of Southern California  
4650 Sunset Blvd  
Los Angeles, CA 90027  
USA  
e-mail: mmuschen@chla.usc.edu